16 results
Thumbnail

D2.326 - The frequency of hereditary α-tryptasemia (HαT) in patenits with insect venom anaphylaxis and in patients with mastocytosis – preliminary results

Thumbnail

D2.324 - Anaphylaxis in very early childhood: An ongoing challenge

Thumbnail

D2.325 - Desensitization of Olipudase alfa-induced anaphylaxis in a child with chronic neurovisceral acid sphingomyelinase deficiency and ochoa syndrome

Thumbnail

D2.327 - Patient and caregiver perspectives on sublingual adrenaline for anaphylaxis: findings from an international survey

Thumbnail

D2.329 - Profilin-mediated anaphylaxis with cofactor

Thumbnail

D2.331 - An Adult Case of Cofactor-Induced Anaphylaxis Associated with Physical Exercise

Thumbnail

D2.441 - Association of High Sensitive-C-reactive Protein with Left Ventricle Remodeling in Type 1 Diabetes Mellitus

Thumbnail

D2.443 - Serum Zonulin Reflects Disease Activity and Psychiatric Burden in Hereditary Angioedema

Thumbnail

D3.419 - Efficacy, safety, and remission outcomes of omalizumab in elderly patients with severe allergic asthma: a subgroup analysis by age of onset

Thumbnail

D3.420 - Real-world epidemiologic characteristics of patients treated with dupilumab for type 2 inflammatory indications: a single-center retrospective cohort study

Thumbnail

D3.422 - Dupilumab in children with multimorbid atopic phenotype: therapy efficacy, safety and biomarker changes

Thumbnail

D3.424 - Retrospective Analysis of Self-Administration of Biologic Treatments for Severe Asthma and Chronic Urticaria

Thumbnail

D3.426 - Predicting response to omalizumab in patients with chronic spontaneous urticaria: The first results of the global multicenter UCARE SCOPUS project

Thumbnail

D3.427 - Challenging the paradigm: Use of omalizumab in refractory angioedema in a 2-year-old child

Thumbnail

D3.428 - Substratification of Biologic Treatment Using Dupilumab in Eosinophilic COPD

Thumbnail

D3.417 - Dupilumab in pediatric patients with severe atopic dermatitis